AbbVie Inc. (ABBV)

Compare

208.70

+3.41

+(1.66%)

As of 2:16:07 PM EDT. Market Open.

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

PR Newswire 6 hours ago

ABBV
+1.66%
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

Building a retirement portfolio of $1 million or more is within reach for many Americans. AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability. A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.

Motley Fool 9 hours ago

ABBV
+1.66%
ISRG

SMMT
AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield

We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years […]

Insider Monkey 18 hours ago

ABBV
+1.66%
3 Relatively Safe Stocks to Buy Right Now

Investing in stocks comes with risks. David Jagielski (Abbott Laboratories): If you're looking for safety within the healthcare sector, a top name to consider right now is Abbott Laboratories. For starters, it offers an above-average dividend yield of 1.9% (the S&P 500 average is 1.4%).

Motley Fool 2 days ago

ABBV
+1.66%
JNJ
+1.19%
ABT
+1.13%
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks 4 days ago

ABBV
+1.66%
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.

Zacks 4 days ago

VKTX

AMGN
+1.22%
ROG.SW
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

Despite a significant revenue drop, CollPlant Biotechnologies Ltd (CLGN) focuses on promising collaborations and innovative product developments to drive future growth.

GuruFocus.com 4 days ago

ABBV
+1.66%
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn in the broader market, with major indexes like the S&P 500 and Nasdaq seeing declines of 1% and 2% respectively, AbbVie managed an 11.86% increase in its stock price over the last quarter. This period also included critical...

Simply Wall St. 5 days ago

ABBV
+1.66%
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30, 2025. Presentations include data from novel investigational molecules, ABBV-969 and ABBV-514, across a range of hard-to-treat tumor types.1,2 Additionally, new insights on treatment resistance and novel biomarker identification based on real-world-data analyses are to be prese

PR Newswire 5 days ago

ABBV
+1.66%
These Dividend Stocks Can Protect You From the Next Market Drop

If markets remain rocky, either because of the Trump administration’s trade war or soft economic data, the aristocrats could continue to outperform. “Our favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to ‘hide’ in the event of an economic slowdown or recessionary environment,” he wrote. The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the often known by its ticker, NOBL.

Barrons.com 5 days ago

^GSPC

ABBV
+1.66%
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition. Investors were worried the company spent nearly $9 billion for nothing, which is understandable.

Motley Fool 5 days ago

ABBV
+1.66%
ABT
+1.13%
S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest point in more than a decade.

Investopedia 5 days ago

^GSPC

IP

ABBV
+1.66%
3 Healthcare Stocks in the Doghouse

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.

StockStory 6 days ago

ABBV
+1.66%
IRTC
5 Large Drug Stocks to Watch as Industry Recovers

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio

Zacks 6 days ago

ABBV
+1.66%
PFE
-0.83%
NVS
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.

Zacks 6 days ago

ABBV
+1.66%
^GSPC
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.

StockStory 7 days ago

MRNA

BMRN

SRPT
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27– Saturday, March 29, 2025.

PR Newswire 7 days ago

ABBV
+1.66%
Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in?

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 in 2020, […]

Insider Monkey 8 days ago

ABBV
+1.66%
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.

Zacks 10 days ago

JNJ
+1.19%
ABBV
+1.66%
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four quarters, like most dividend payers) is currently $6.56. You'll get 152, which is the number of shares you'd need to own for a year to get $1,000 in dividend payments. Note, too, that like many healthy and growing dividend payers, AbbVie has been hiking its payout annually.

Motley Fool 11 days ago

ABBV
+1.66%

Performance Overview

Return	ABBV	S&P 500 (^GSPC)
YTD	+18.55%	-5.11%
1-Year	+18.78%	+6.22%
3-Year	+44.11%	+23.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV)

AbbVie to Host First-Quarter 2025 Earnings Conference Call

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield

3 Relatively Safe Stocks to Buy Right Now

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

These Dividend Stocks Can Protect You From the Next Market Drop

2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income

S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook

3 Healthcare Stocks in the Doghouse

5 Large Drug Stocks to Watch as Industry Recovers

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in?

J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

Performance Overview